A recent clinical trial reveals how a daily statin pill may prevent heart attacks and strokes in people with HIV. In this substudy of the phase 3 Randomized Trial to Prevent Vascular Events in HIV ...
COURAGE Substudy: Anatomy Trumps Ischemia for Predicting Outcomes Among patients with stable ischemic heart disease, baseline assessment of anatomic burden predicts future events, but evaluation of ...
Objectives Observational studies suggest that acid suppression may worsen outcomes among patients infected with SARS-CoV-2. The objectives of this embedded substudy of a randomised controlled trial ...
A long-standing request to clarify data irregularities in a 2021 ISCHEMIA substudy resulted in the publication of one correction, with a second correction in the works. Further, the lone cardiac ...
LOS ANGELES, CA—Among medically managed patients with acute coronary syndromes (ACS) but no ST-segment elevation, prasugrel is associated with lower platelet reactivity than clopidogrel, irrespective ...
The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis ...
Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these ...
Adding PCI to optimal medical therapy didn't improve clinical end points among the patients with stable CAD randomized in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug ...
Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab ...
Hosted on MSN
Daiichi Sankyo’s ADC push in gastroesophageal cancer: What substudy 06D means for investors
Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study. Study Overview: Substudy 06D, formally titled “A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate ...
Industry and patient groups have asked the US Food and Drug Administration (FDA) to make several changes to its revised draft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results